Navigation Links
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
Date:9/12/2011

velopment activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego and has a commercial manufacturing facility in Ohio.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Mass., Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

This press release contains forward-looking statements about Amylin, Lilly and Alkermes. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYDUREON may not be approved by the FDA in a timely manner or at all; the information provided in the companies' response to the FDA's complete response letter may not satisfy the FDA; the FDA may request additional information prior to a
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... has priced its previously announced public offering of common ... will issue 23,529,412 common shares at a price of ... $2.0 billion. The Company will file a final prospectus ... S-3 and will make a similar filing with the ...
(Date:6/18/2013)...  Actavis, Inc. (NYSE: ACT ) today announced ... Securities and Exchange Commission (SEC) a registration statement on Form ... Chilcott plc (NASDAQ: WCRX ), which included ... (the "Form S-4"). As previously announced on ... entered into a definitive agreement pursuant to which Actavis will ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
... Ga., Dec. 23, 2010 MiMedx Group, ... integrated developer, manufacturer and marketer of patent protected biomaterial-based ... the Class III certification for a European product using ... certification for "post surgical adhesion inhibiting barriers" is in ...
... Pa., Dec. 23, 2010 Cephalon, Inc. (Nasdaq: ... appointed J. Kevin Buchi as Chief Executive Officer and a ... role of company Chairman in the future. William P. Egan ... "Kevin is an experienced pharmaceutical executive who has been ...
Cached Medicine Technology:MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 2MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 3MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 4Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 2Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 3Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 4
(Date:6/19/2013)... Pharmaceutical history is replete with ... with little or no understanding why they work, ... involved emerging years later. When Edward Tobinick ... rapid recovery of cognitive functions after perispinally administering ... known about the role inflammatory processes play in ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Middle ... throughout 2013 across all industries as cash rich buyers ... the differences across industries, all M&A transactions have a ... due diligence to verify the history and quality of ... considered. , But when due diligence involves a ...
(Date:6/19/2013)... Over the past five years, revenue ... has been growing at an annualized rate of 9.5% ... have supported the development of the industry including: substantial ... relatively higher drug prices in hospitals; and people's increased ... the development of chain drug retailing enterprises has also ...
(Date:6/18/2013)... Angeles, CA (PRWEB) June 19, 2013 ... of bariatric surgery, are holding complimentary weight loss seminars ... the detailed program can be accessed at their official ... minimizes surgery and recovery time. Their highly skilled panel ... to bariatric surgery. , A senior executive working ...
(Date:6/18/2013)... 18, 2013 Exposed Skin Care has finally ... acne suffers of all ages finally achieve the clear, beautiful ... products, this new acne clearing system combines the power of ... new acne from forming. , After a quick ... products are some of the most effective available on the ...
Breaking Medicine News(10 mins):Health News:Perispinally Administered Enbrel Facilitates Rapid Recovery of Cognitive Function in Patients with Alzheimer's 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3
... VANCOUVER, APRIL 1, 2009 New research funded by ... and learning difficulties for some childhood cancer survivors, especially ... in the journal Cancer , raises critical questions ... , "These are very significant findings," says Barbara Kaminsky, ...
... nurses, doctors and other front line cancer-care providers significantly ... with other healthcare workers, and with their own family, ... and Regenstrief Institute researchers published in the March issue ... , "The healthcare field is becoming more aware of ...
... new study, a therapeutic agent called sorafenib dramatically improved the ... approved in several countries for treatment of kidney and liver ... patients suffering from advanced portal hypertension, the authors suggest. Their ... a journal published by John Wiley & Sons on behalf ...
... out to adopt a child, the world pays attention. ... Malawi -- a small impoverished African nation. In ... to over a million, help is needed in many forms. ... with a mother and siblings, and the essentials of childhood ...
... physician groups clearly understand how to effectively analyze ... to be more innovative and establish more effective ... consultants The Practice Pros and Mediplay, Inc. have ... with assessing their marketing effectiveness. To take ...
... marketer of PurinaCare (R) Pet Health Insurance ( ... ( www.kgbtexas.com ) as its PR agency of ... June 2008, and is currently authorized to market pet health ... will help create and implement a strategic public relations and ...
Cached Medicine News:Health News:New research shows lower educational outcomes for survivors of childhood cancer 2Health News:Compassion fatigue: Impact on healthcare providers of caring for the terminally ill 2Health News:Compassion fatigue: Impact on healthcare providers of caring for the terminally ill 3Health News:Medication may improve portal hypertension 2Health News:In Malawi, Adoption is Not Enough 2Health News:Hey Doc, What's Your Marketing Strategy? 2Health News:Hey Doc, What's Your Marketing Strategy? 3Health News:KGBTexas Named Public Relations Agency of Record for PurinaCare(R) Pet Health Insurance 2Health News:KGBTexas Named Public Relations Agency of Record for PurinaCare(R) Pet Health Insurance 3
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... 4F, 5F, and 6F ... is ideal for coronary ... state-of-the-art technology and proprietary ... better responsiveness, optimal torque, ...
Medicine Products: